PL2079482T3 - Zastosowanie przeciwciała anty-CD151 do leczenia nowotworu pierwotnego - Google Patents

Zastosowanie przeciwciała anty-CD151 do leczenia nowotworu pierwotnego

Info

Publication number
PL2079482T3
PL2079482T3 PL07858450T PL07858450T PL2079482T3 PL 2079482 T3 PL2079482 T3 PL 2079482T3 PL 07858450 T PL07858450 T PL 07858450T PL 07858450 T PL07858450 T PL 07858450T PL 2079482 T3 PL2079482 T3 PL 2079482T3
Authority
PL
Poland
Prior art keywords
antibody
treatment
protein
primary cancer
cancer
Prior art date
Application number
PL07858450T
Other languages
English (en)
Inventor
Jean-François Haeuw
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2079482(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PL2079482T3 publication Critical patent/PL2079482T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07858450T 2006-10-18 2007-10-15 Zastosowanie przeciwciała anty-CD151 do leczenia nowotworu pierwotnego PL2079482T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (fr) 2006-10-18 2006-10-18 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
PCT/FR2007/001688 WO2008049990A2 (fr) 2006-10-18 2007-10-15 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
EP07858450A EP2079482B1 (fr) 2006-10-18 2007-10-15 Utilisation d'un anticorps anti-cd151 pour le traitement de cancer primaire

Publications (1)

Publication Number Publication Date
PL2079482T3 true PL2079482T3 (pl) 2011-07-29

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07858450T PL2079482T3 (pl) 2006-10-18 2007-10-15 Zastosowanie przeciwciała anty-CD151 do leczenia nowotworu pierwotnego

Country Status (28)

Country Link
US (2) US8178096B2 (pl)
EP (1) EP2079482B1 (pl)
JP (2) JP5757646B2 (pl)
KR (1) KR101521863B1 (pl)
CN (1) CN101528256B (pl)
AT (1) ATE499387T1 (pl)
AU (1) AU2007310763B2 (pl)
BR (1) BRPI0717455A2 (pl)
CA (1) CA2665912C (pl)
DE (1) DE602007012743D1 (pl)
DK (1) DK2079482T3 (pl)
ES (1) ES2361696T3 (pl)
FR (1) FR2907341B1 (pl)
HK (1) HK1132904A1 (pl)
HR (1) HRP20110374T1 (pl)
IL (1) IL198043A (pl)
MA (1) MA30777B1 (pl)
MX (1) MX2009003039A (pl)
NO (1) NO20091919L (pl)
NZ (1) NZ575781A (pl)
PL (1) PL2079482T3 (pl)
PT (1) PT2079482E (pl)
RS (1) RS51729B (pl)
RU (1) RU2464041C2 (pl)
SI (1) SI2079482T1 (pl)
TN (1) TN2009000144A1 (pl)
UA (1) UA99601C2 (pl)
WO (1) WO2008049990A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (zh) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
CN109219620B (zh) 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
CN108690136B (zh) * 2017-04-05 2022-09-20 凯惠科技发展(上海)有限公司 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ
JP2003321494A (ja) 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
EP2041175A4 (en) * 2006-06-23 2011-03-16 Augmenta Biolog Llc TARGETED IMMUNOJUGATE
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
US20120219569A1 (en) 2012-08-30
PT2079482E (pt) 2011-05-25
JP2010506888A (ja) 2010-03-04
SI2079482T1 (sl) 2011-07-29
TN2009000144A1 (fr) 2010-10-18
CN101528256B (zh) 2013-10-02
CA2665912C (fr) 2014-12-09
JP2013253084A (ja) 2013-12-19
EP2079482B1 (fr) 2011-02-23
DK2079482T3 (da) 2011-06-14
AU2007310763B2 (en) 2011-02-17
JP5757646B2 (ja) 2015-07-29
NO20091919L (no) 2009-05-18
JP5723420B2 (ja) 2015-05-27
KR101521863B1 (ko) 2015-05-20
RS51729B (en) 2011-10-31
FR2907341B1 (fr) 2012-08-17
US20090324600A1 (en) 2009-12-31
HRP20110374T1 (hr) 2011-06-30
MA30777B1 (fr) 2009-10-01
WO2008049990A3 (fr) 2008-09-12
NZ575781A (en) 2012-06-29
FR2907341A1 (fr) 2008-04-25
MX2009003039A (es) 2009-04-02
BRPI0717455A2 (pt) 2013-12-24
RU2009118440A (ru) 2010-11-27
RU2464041C2 (ru) 2012-10-20
IL198043A (en) 2015-03-31
US8178096B2 (en) 2012-05-15
KR20090067219A (ko) 2009-06-24
UA99601C2 (ru) 2012-09-10
EP2079482A2 (fr) 2009-07-22
ATE499387T1 (de) 2011-03-15
WO2008049990A2 (fr) 2008-05-02
ES2361696T3 (es) 2011-06-21
DE602007012743D1 (de) 2011-04-07
IL198043A0 (en) 2011-08-01
CA2665912A1 (fr) 2008-05-02
CN101528256A (zh) 2009-09-09
HK1132904A1 (en) 2010-03-12
AU2007310763A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
HK1132904A1 (en) Use of an anti-cd151 antibody in the treatment of cancer
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX2009005597A (es) Miembros de enlace para interleucina 6.
NZ786274A (en) Human antibodies against tissue factor
BRPI0606891A2 (pt) anticorpos dr5 e usos dos mesmos
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
AU2010220421A8 (en) Antibodies against a proliferating inducing ligand (APRIL)
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
DE602007009204D1 (de) Von kollagen typ iv abgeleitetes cyclopeptid mit antikrebswirkung
AU2017236047B2 (en) Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
UA98756C2 (ru) Антитело, которое связывается с cd38, для лечения заболевания, опосредованного cd38
EA202090198A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
FR2929519B1 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement precoce des cancers.
UA107655C2 (uk) Селективні інгібітори антиапоптичних білків bcl-2 для лікування раку і імунних захворювань